NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Neurothera Labs and Clearmind Medicine's Israeli Patent Application for Non-Hallucinogenic Depression Treatment
TL;DR
Neurothera Labs' new patent filing for MEAI and PEA combination therapy could provide a competitive edge in the $280 million depression treatment market.
The therapy combines MEAI and N-Acylethanolamines like PEA, targeting depression through preclinical data showing efficacy while preserving natural reward pathways.
This innovative depression treatment could improve quality of life for millions worldwide affected by major depressive disorder, a leading cause of disability.
Neurothera Labs' 13th patent filing combines MEAI with PEA, expanding their portfolio for treating depression, addiction, and obesity through novel drug combinations.
Found this article helpful?
Share it with your network and spread the knowledge!
Neurothera Labs announced that Clearmind Medicine has filed an Israeli patent application for an innovative combination therapy of MEAI and N-Acylethanolamines like PEA to treat depression.
The therapy combines 5-methoxy-2-aminoindane (MEAI) with N-Acylethanolamines, specifically mentioning Palmitoylethanolamide (PEA) as an example.
This therapy represents a novel non-hallucinogenic neuroplastogen approach to treating depression, addressing a major global health issue with limited innovative treatment options currently available.
According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability.
Neurothera Labs Inc. (a wholly-owned subsidiary of SciSparc Ltd.) is collaborating with Clearmind Medicine Inc. on this patent application and broader partnership.
The collaboration has filed 13 patents focusing on MEAI and N-Acylethanolamines combinations for alcohol use disorder, cocaine addiction, obesity and weight loss, and depression.
Preclinical data supports MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.
Neurothera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
For further information, contact Michal Efraty, IR Manager at Neurothera Labs Inc., at telephone: 972-3-7617108 or email: michal@efraty.com
This is a patent application stage, and the company is advancing MEAI-based treatments toward clinical development, though no specific timeline is provided in the release.
Curated from NewMediaWire
